Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?
作者信息
Patel Niralee, Hindi Judy, Farouk Samira S
机构信息
Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Kidney360. 2021 Apr 22;2(7):1174-1178. doi: 10.34067/KID.0000732021. eCollection 2021 Jul 29.
Abstract
摘要
相似文献
1
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?钠-葡萄糖协同转运蛋白2抑制剂与肾移植：我们还在等什么？
Kidney360. 2021 Apr 22;2(7):1174-1178. doi: 10.34067/KID.0000732021. eCollection 2021 Jul 29.
2
Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.钠-葡萄糖协同转运蛋白2抑制剂在患有2型糖尿病或移植后糖尿病的实体器官移植受者中的应用：一项系统评价。
Transplant Rev (Orlando). 2023 Jan;37(1):100729. doi: 10.1016/j.trre.2022.100729. Epub 2022 Nov 4.
3
Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients.SGLT2抑制剂在糖尿病肾移植患者中的应用结果
Transplant Proc. 2020 Jan-Feb;52(1):175-178. doi: 10.1016/j.transproceed.2019.11.007. Epub 2020 Jan 7.
4
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Renal Transplant Patients With Diabetes: A Brief Review of the Current Literature.钠-葡萄糖共转运蛋白 2 抑制剂在糖尿病肾移植患者中的应用：对当前文献的简要回顾。
Can J Diabetes. 2022 Mar;46(2):207-212. doi: 10.1016/j.jcjd.2021.06.003. Epub 2021 Jun 19.
5
Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.在英国临床环境中，与二肽基肽酶-4 抑制剂相比，钠-葡萄糖共转运蛋白-2 抑制剂可显著减少 2 型糖尿病成人的慢性肾脏病进展：基于肾脏病国际指南的观察性结局研究。
Diabetes Obes Metab. 2022 Nov;24(11):2138-2147. doi: 10.1111/dom.14799. Epub 2022 Jul 6.
6
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
7
A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂开创糖尿病肾病治疗新纪元。
J Diabetes Investig. 2022 May;13(5):765-767. doi: 10.1111/jdi.13747. Epub 2022 Feb 3.
8
Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.使用钠-葡萄糖共转运蛋白 2 抑制剂治疗艾伯塔省慢性肾病成人患者：一项横断面研究，旨在确定差距以促进知识转化。
CMAJ Open. 2023 Jan 31;11(1):E101-E109. doi: 10.9778/cmajo.20210281. Print 2023 Jan-Feb.
9
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.抑制钠-葡萄糖共转运蛋白 2 以减缓慢性肾脏病的进展。
Acta Clin Belg. 2022 Aug;77(4):805-814. doi: 10.1080/17843286.2021.1966583. Epub 2021 Aug 17.
10
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.钠-葡萄糖共转运蛋白 2 抑制剂的肾保护机制：关注肾脏血流动力学。
Diabetes Metab J. 2022 Jul;46(4):543-551. doi: 10.4093/dmj.2022.0209. Epub 2022 Jul 27.
引用本文的文献
1
Dapagliflozin's Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients.达格列净对糖尿病和非糖尿病肾移植受者尿白蛋白及非白蛋白蛋白的影响
Biomedicines. 2025 May 26;13(6):1303. doi: 10.3390/biomedicines13061303.
2
SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations.患有泌尿生殖系统畸形和尿路改道患者使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：风险、益处及临床考量
Medicina (Kaunas). 2025 May 20;61(5):921. doi: 10.3390/medicina61050921.
3
Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients.钠-葡萄糖协同转运蛋白2抑制剂在肾移植受者中的应用。
World J Transplant. 2023 Sep 18;13(5):239-249. doi: 10.5500/wjt.v13.i5.239.
4
Screening and Management of Coronary Artery Disease in Kidney Transplant Candidates.肾移植候选者冠状动脉疾病的筛查与管理
Diagnostics (Basel). 2023 Aug 20;13(16):2709. doi: 10.3390/diagnostics13162709.
5
Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review.用于糖尿病肾移植患者管理的新型药物：文献综述
Life (Basel). 2023 May 26;13(6):1265. doi: 10.3390/life13061265.
6
New-Onset Diabetes Mellitus in Post-renal Transplant Patients on Tacrolimus and Mycophenolate: A Systematic Review.肾移植术后接受他克莫司和霉酚酸酯治疗患者的新发糖尿病：一项系统评价
Cureus. 2022 Nov 14;14(11):e31482. doi: 10.7759/cureus.31482. eCollection 2022 Nov.
7
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review.SGLT2 抑制剂在慢性肾脏病和心脏病患者中的应用：文献综述。
Methodist Debakey Cardiovasc J. 2022 Sep 6;18(4):62-72. doi: 10.14797/mdcvj.1120. eCollection 2022.
8
Diabetes in Kidney Transplantation.肾脏移植中的糖尿病。
Adv Chronic Kidney Dis. 2021 Nov;28(6):596-605. doi: 10.1053/j.ackd.2021.10.004.
本文引用的文献
1
Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics.钠-葡萄糖协同转运蛋白2抑制剂的实际处方：如何处理其他药物，包括降糖药和利尿剂。
Kidney360. 2021 Feb 1;2(4):742-746. doi: 10.34067/KID.0000412021. eCollection 2021 Apr 29.
2
Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients.糖尿病肾病移植受者中钠-葡萄糖协同转运蛋白抑制剂（SGLT-2i）的早期应用及相关代谢和电解质结局。
Endocrinol Diabetes Metab. 2020 Sep 13;4(2):e00185. doi: 10.1002/edm2.185. eCollection 2021 Apr.
3
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.
4
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
5
SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study.钠-葡萄糖协同转运蛋白2抑制剂与福尼尔坏疽住院风险：一项巢式病例对照研究
Diabetes Ther. 2020 Mar;11(3):711-723. doi: 10.1007/s13300-020-00771-8. Epub 2020 Feb 12.
6
Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients.SGLT2抑制剂在糖尿病肾移植患者中的应用结果
Transplant Proc. 2020 Jan-Feb;52(1):175-178. doi: 10.1016/j.transproceed.2019.11.007. Epub 2020 Jan 7.
7
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.接受 SGLT2 抑制剂治疗的患者的急性肾损伤和不良肾脏事件：系统评价和荟萃分析。
PLoS Med. 2019 Dec 9;16(12):e1002983. doi: 10.1371/journal.pmed.1002983. eCollection 2019 Dec.
8
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases.恩格列净在肾移植受者中的应用：8例报告。
Transplant Proc. 2019 Dec;51(10):3275-3280. doi: 10.1016/j.transproceed.2019.05.023. Epub 2019 Nov 13.
9
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在糖尿病肾病移植受者中的应用。
Kidney Blood Press Res. 2019;44(5):984-992. doi: 10.1159/000501854. Epub 2019 Aug 22.
10
Efficacy and Safety of Canagliflozin in Kidney Transplant Patients.卡格列净在肾移植患者中的疗效与安全性
Indian J Nephrol. 2019 Jul-Aug;29(4):278-281. doi: 10.4103/ijn.IJN_2_18.
Zotero 插件